Pharmaceutical compositions for the treatment of autoimmune diseases comprising the B-oligomer of pertussis toxin or its subunits
AssigneeYeda Research and Development Co. Ltd.
InventorAvraham Ben-Nun
Life of this patent
Estimating the term…
Abstract
The invention provides the use of a protein selected from the B-oligomer of pertussis toxin, an individual subunit S2, S3, S4 or S5 thereof, or a combination of the subunits, for the preparation of pharmaceutical compositions comprising them for the treatment of autoimmune diseases.
Claims9
A pharmaceutical composition for the treatment of autoimmune diseases comprising, as active ingredient, the S2/S4 heterodimer of the B-oligomer of pertussis toxin (PT), the S3/S4 heterodimer of the B-oligomer of PT, or a mixture of both heterodimers, in an amount effective for treating autoimmune diseases, and a pharmaceutically acceptable carrier.
A method for the treatment of a patient afflicted with an autoimmune disease which comprises administering to said patient an effective amount of a material selected from the group consisting of the S2/S4 heterodimer of the B-oligomer of pertussis toxin (PT), the S3/S4 heterodimer of the B-oligomer of PT, and a mixture of both heterodimers.
Dependencies are inferred from the claim text.